Bayer's Nexavar has had the first-line liver cancer space to itself for years, but Eisai is doing its best to change that.

Sun's U.S. sales dropped 34% last quarter, Grail is merging with Hong Kong-based Cirina, Shanghai-based InventisBio raised $19 million in series B.

A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same…

Sun Pharma has suffered a gut-wrenching drop in its sales in the U.S. as ongoing regulatory restraints for Sun Pharma’s key API plant in India, along with…

Earlier this month, the FDA banned all products being shipped to the U.S. by a Chinese API maker, and a new warning letter explains why. It appears the…

Problems at Lupin’s plant in Goa, India, hit the drugmaker’s latest earnings with a double whammy, undercutting its U.S. sales while raising costs.

GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.

India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.…

Pharma Asia